List of works - Qaiser Bashir

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

scientific article published on 3 July 2017

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

scientific article

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

scientific article

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

scientific article published on 31 March 2015

Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

scientific article published on 28 November 2019

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

scientific article published on 01 March 2019

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

scientific article published on 27 March 2015

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

scientific article

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

scientific article published on 01 October 2020

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results

scientific article published on 2 November 2016

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

scientific article published on 11 January 2019

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

scientific article published on 30 June 2020

Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning

scientific article published on 21 March 2017

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation

scientific article published in 2022

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

scientific article published on 20 May 2016

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

scientific article

Durable remission with salvage second autotransplants in patients with multiple myeloma

scientific article

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

scientific article

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

scientific article published on 12 February 2018

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

scientific article published on 16 March 2015

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

scientific article published on 24 August 2011

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

scientific article published on 01 November 2018

HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant

scientific article published on 23 January 2019

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

scientific article published on 13 September 2017

Haploidentical Transplants for Patients with Graft Failure After the First Allograft

scientific article published on 29 June 2020

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

scientific article published on 21 October 2019

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

scientific article

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

scientific article published on 15 May 2017

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

scientific article

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

scientific article published on 22 July 2018

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis

scientific article

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity

scientific article published on 01 April 2020

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis

scientific article published on 03 September 2019

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

scientific article published on 11 February 2019

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

scientific article published on 4 January 2017

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

scientific article published on 09 August 2018

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

scientific article published on 03 June 2020

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome

scientific article published on 26 September 2018

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

scientific article

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

scientific article

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

scientific article

Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

scientific article published on 01 February 2020

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome

scientific article published on 21 December 2018

Melphalan based autologous transplant in octogenarian multiple myeloma patients

article

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation

scientific article published on 11 July 2019

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

scientific article published on 04 April 2019

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

scientific article

Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation

scientific article published on 10 September 2019

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

scientific article published on 24 December 2019

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

scientific article published on December 2015

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

scientific article published on 2 April 2015

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation

scientific article

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

scientific article published on 17 May 2017

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

scientific article published on 16 January 2016

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

scientific article

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

scientific article published on 15 July 2016

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

scientific article published on 08 July 2019

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia

scientific article published on 26 June 2019

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma

scientific article published on 10 February 2017

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

scientific article

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

scientific article

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

scientific article published on 18 August 2016

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

scientific article published on 28 March 2017

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

scientific article published on 9 November 2016

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

scientific article published on 09 January 2012

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

scientific article published on 16 November 2018

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations

scientific article published on 16 May 2018

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

scientific article published on 28 September 2016

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

scientific article

Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant ⬇️

scientific article published on 05 December 2011

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

scientific article published on 12 July 2016

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

scientific article published on 15 July 2014

Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

scientific article published on 26 February 2020

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission

scientific article

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

scientific article

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation

scientific article published on 26 October 2013

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

scientific article

Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission ⬇️

scientific article published on November 16, 2010

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

scientific article published on 19 December 2017

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

scientific article published on 10 June 2015

List of works by Qaiser Bashir

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Durable remission with salvage second autotransplants in patients with multiple myeloma

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Haploidentical Transplants for Patients with Graft Failure After the First Allograft

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome

Melphalan based autologous transplant in octogenarian multiple myeloma patients

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant ⬇️

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib